ArticleScientific reports2020
High serum adiponectin as a biomarker of renal dysfunction: Results from the KNOW-CKD study.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Thiazolidinediones play a positive role in the vascular endothelium and inhibit plaque progression in diabetic patients with coronary atherosclerosis: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Biomarkers and Risk Prediction in Cardiovascular-Kidney-Metabolic Syndrome: A Comprehensive Review.Reviews in cardiovascular medicine · 2026Review
- Assessment of potential nephrotoxicity biomarkers after [Scientific reports · 2026Article
- Article
- Metabolic syndrome and kidney dysfunction: emerging molecular and cellular mechanisms at the metabolic-renal interface.Frontiers in endocrinology · 2026Review
- High serum isthmin-1 as a biomarker for the progression of renal function decline in patients with type 2 diabetes mellitus.BMC endocrine disorders · 2025Article
- Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.International journal of molecular sciences · 2025Review
- Obesity-related glomerulopathy: How it happens and future perspectives.Diabetic medicine : a journal of the British Diabetic Association · 2025Review
- The Effect of Kidney Transplantation and Immunosuppressive Therapy on Adipose Tissue Content and Adipocytokine Plasma Concentration-Preliminary Study.Current issues in molecular biology · 2025Article
- Adiponectin and All-Cause Mortality in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis.Metabolites · 2025Review
- Metabolic Response After a Single Maximal Exercise Session in Physically Inactive Young Adults (EASY Study): Relevancy of Adiponectin Isoforms.Biomolecules · 2025Article
- Urinary Fetuin-A with Specific Post-Translational Modification in Type 1 Diabetes Patients with Normoalbuminuria and Preserved Kidney Function.Diagnostics (Basel, Switzerland) · 2025Article
- Pathogen Resistance and Biomarker-Based Diagnosis of Postoperative Urinary Tract Infections in Kidney Stone Patients.Infection and drug resistance · 2025Article
- Influence of serum adiponectin on baseline albuminuria and subsequent decline in eGFR in African Americans: The Jackson Heart Study.PloS one · 2025Article
- Molecular Insight into Obesity-Associated Nephropathy: Clinical Implications and Possible Strategies for its Management.Current drug targets · 2025Review
- Bone marrow adipose tissue expansion and bone loss in experimental chronic kidney disease is independent of altered bone marrow stromal cell lineage determination.Frontiers in endocrinology · 2025Article
- Prevalence and Risk Factors of Plasma Adiponectin Deficiency: A Cross-Sectional Study in a Physical Examination Cohort from Southwest China.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Adiposity and Mineral Balance in Chronic Kidney Disease.Current osteoporosis reports · 2024Review
- Article
- Preliminary Report on the Influence of Acute Inflammation on Adiponectin Levels in Older Inpatients with Different Nutritional Status.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High serum adiponectin is noted in several conditions of chronic kidney disease (CKD) and is a predictor for end stage renal disease. However, the relationship between adiponectin level and renal disease progression is not well established. This study aimed to determine the relationship between serum adiponectin levels and CKD progression. This prospective longitudinal study included 2238 patients from the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease. Patients were divided into quartiles according to their serum adiponectin level. Composite renal outcome was defined as one or more of the following: initiation of dialysis or transplantation, a two-fold increase in baseline serum creatinine levels, or a 50% decline in the estimated glomerular filtration rate (eGFR) during the follow-up period. A cox proportional hazard ratio model was applied to analyze the relationship between composite renal outcome and serum adiponectin levels. Serum adiponectin level was inversely associated with eGFR (p < 0.001) and positively correlated with urine albumin-creatinine ratio. The highest quartile of serum adiponectin was associated with an increased risk of adverse renal outomes (HR, 1.39; 95%CI, 1.05-1.84; p=0.021). On time-dependent receiver operating characteristic curve analysis, predictive ability of adiponectin for renal outcomes disappeared after adjusting for eGFR. Therefore, serum adiponectin may be a biomarker of renal dysfunction rather than a true risk factor in CKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.